Abstract
Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioguanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioguanine is not felt to have significant antitumor activity in this patient population.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Aged
-
Carcinoma, Small Cell / drug therapy*
-
Drugs, Investigational / administration & dosage*
-
Drugs, Investigational / adverse effects
-
Female
-
Humans
-
Infusions, Intravenous
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Prognosis
-
Thioguanine / administration & dosage*
-
Thioguanine / adverse effects
-
Time Factors
Substances
-
Drugs, Investigational
-
Thioguanine